ACATAGATATATAACACTATTGTTTCCGTTTTGGCCAAGTTAAGGAGCAGAATATTCTCACAGC CCAAAAAGCCGCTGCCGAGCTGCTGTGAGAATTTTTACTGCCTTTGTTGAATATTTATGCATTT GTTGCTGTTGCTGTCTTTACAGATTTACAAATTAAGATTCGCAGTTTTGAATTAATTATCGCTC ACTTCCG >Dmel_ASE5M2
CCTAAGGgttctatagttttcttcggttggtaaggcccggtCTGTGGGAATcggcaaactgcTC GTGTGAATcgggggcccaccccacctgtactagCTTCCCACGAgttgggtaagaccaaaaagat tcatttaatcagggccggcgctgggttgagttccggtagtccatatcctggcctcctacccgcg cacgctcgcgcgccacagcggtgggaatggggttaacctggccttctactccgATTCTCACAGa aaccccctaatagtaatctagtCTGTGAGAATggggcagtaagggtggtccgcgggcgtacggg tggtagtggtagtgagggcactcgggcacccggcctcggatactggggtccggccggcgataga caggaat
Design of primer sequences for synthesizing ASE5
To accelerate the introduction of large blocks of mutations (non-complementary transversions: A <-> C and G <-> T) into ASE5, we synthesized the enhancer fragment de novo by recursive PCR [22], using nine forward primers and nine reverse primers as listed below. The forward primer sequences do not overlap with each other, but each primer overlaps with two adjacent reverse primers by 20 bases each. The 5' and 3' end primers include EcoRI and BamHI restriction sites, respectively. To generate ASE5 mutants or ASE5-shuffle variants, primers containing mutated or shuffled sequences were used instead of their wild-type counterparts in the recursive PCR.
The primers used for synthesizing wild-type ASE5 are shown below; primer sequences used for making ASE5 mutants and other variants are available upon request.
Lower-case letters denote restriction sites (bold) and end-protecting nucleotides. 
Yeast one-hybrid screens
We performed two separate yeast one-hybrid screens, with either Fragment X or Fragment Y of ASE5 (see Figure S1A ) as bait, using the Matchmaker Yeast One-Hybrid System (Clontech). The cDNA library used in the screen was prepared from stage-13 embryos, when embryo socket cells are newly born.
The Fragment Y bait was generated by PCR; the Fragment X bait by annealing two synthetic complementary oligonucleotides (Integrated DNA Technologies). A cDNA library was generated from 2 µg of total RNA from stage-13 embryos, and was cloned into the prey plasmid as a fusion with GAL4AD coding sequences by in vivo recombination according to the manufacturer's instructions. High-efficiency yeast transformation was performed as described [29] . Positive clones were selected on synthetic defined media -Trp -Leu -His, plus 10 mM 3-AT. In total, 1.2 million clones were screened with bait Y, and 0.6 million clones with bait X. For each screen, 100 independent clones from selection plates were serially streaked three times on fresh selection plates, after which the cDNA insert was amplified from individual clones by PCR and sequenced. Identity of the clones was determined by BLAST analysis against the Drosophila melanogaster genome.
With Fragment Y as bait, a significant fraction of positively selected clones (13/75) contained a cDNA fragment encoding Ventral veins lacking (Vvl), a POU-HD transcription factor [30, 31] . By contrast, the screen using Fragment X as bait did not yield obvious candidates. See Table S1 and Table S2 for details.
Identification of Vvl binding motifs in ASE5
We found that an eight-nucleotide motif (ATGCAAAT) located in ASE5 Fragment Y perfectly matches a previously characterized Vvl binding site [12] . Using an electrophoretic mobility shift assay (EMSA), we confirmed that this motif, designated V1, is bound specifically in vitro by a purified GST-Vvl fusion protein (see below and Figure S3 ). To determine if other Vvl binding sites are contained within ASE5, we used double-stranded oligonucleotides covering the entire ASE5 as competitors in the EMSA, which led to the discovery that the AATTAA motif is also bound strongly by GST-Vvl (see Figure S3 ).
Electrophoretic mobility shift assays (EMSAs)
The complete vvl coding sequence was obtained by PCR from a cDNA library of stage-13 embryos (strain w 1118 ), and cloned into vector pGEX-5X-2 (GE Healthcare Life Sciences). The GST-Vvl fusion protein was expressed in E. coli strain BL21, and purified according to the manufacturer's instructions. The concentration of the purified protein was estimated by comparing it with BSA standards in a Coomassie-stained 4-20% SDS-PAGE gel (Bio-Rad Laboratories, Inc.).
Oligonucleotides used for EMSA probes were labeled with Biotin-11-UTP and annealed in vitro according to the manufacturer's instructions (Thermo Scientific). For each EMSA reaction, approximately 10 µg of purified GST-Vvl was incubated with 20 pmol of labeled probe for 20 minutes at room temperature. Free and bound probes were separated on 5% non-denaturing polyacrylamide gels (Bio-Rad) and detected using the LightShift Chemiluminescent EMSA kit according to the manufacturer's instructions (Thermo Scientific). For competition assays, 10 nmol of unlabeled oligonucleotides (500-fold excess) were included in each reaction mix.
Sequences of synthetic enhancers based on ASE5
The synthetic enhancer ASE5-shrink is composed of the essential sequences of ASE5: 
Sequences of the mα enhancer and variants
The mα enhancer was described previously [11]; its sequence is shown below. Su(H) motifs are shaded in green, Vvl binding sites in yellow, and the E-box in blue. The enhancer fragment was PCR-amplified using the following primers: The mαA variant was created by introducing three point mutations into an 11-bp sequence in the mα enhancer (AACCCCAAGAT, shown in bold in the sequence below), thus converting it to the sequence of the A motif (AACGCGAATCT).
The segments underlined in the mα enhancer sequence below were joined to make the mα-shrink enhancer; the "E box" segment was omitted in the construction of the mα-shrink∆E and mα-shrink∆E-Vm variants. Both the mα-Vm and mα-shrink∆E-Vm variants include the same point mutations in the Vvl binding motifs; these are shown in lower case in the mα-shrink∆E-Vm sequence below. TCGCTTTGCACACACTTTCTCCCTGCGCCTTATCGGGTAATCCCTCTCCCTTGAAACAATATTG  AAGAAACCCTCCCTATCGCTCCACACGTTCAGCACACTTGGGCCGCAAGAAAGGGAATTAATTA  AAATATCTATAAGATTCCCAGCTCACCCCTGGGGAGTGTTTCCAAATTGAAGACAAGTGGCAAG  TCCGTATTTTATTGGTGGTGGTTTCGATGGTGCTAGTGAATAGTGGTAAATGGATTCATCGAGC  CCTGTGGGAAAGTTGGAAATCAAAACACCATAACAAGTGATTCGAGATGCCTATACAAATAGAA  GATCCAACCCCAAGATCCCTTATGCCCTTTCATATGCACGAAACCAGAGCCAGGACGAAGCAAT  GTGTGGGAATGCGTGGGAATGGTCCTGGGGATTCGAAACTCAGAAACGGTCCCCTATCCCTGCT  TTTATGTTGATTGCCCATTAGGAATACAATTTGCAACTCCTTTTCCATGATGTGATCCCCTTGT  TGATCCTGGGCTTCCTTCGGTGTCGTGAGAAATTTTACCAAGGAACACCTGCCCCGTATCGGTG  TGTCCTGGATTGCCAGTGTGTTGGTGATTTTTTTCATGTCCTCTGGGGATTTCACGCAGCACTT  GAATACGTTTCCGAAAATTTTGAGGCCAGCGAAAAATTGTTTCCCACACTCGTCGGACAGTTGC  AGTTTTTGTAGGGGTTTGTTTCCTTTGCCGATGCACTCTTCTCTCGTCTCATCCCGTCTCGTCT  TTACCTGCTCCTGGAACTTCCCCCGACTCCTGGCGAGCGTCGTATTTCAGGTTCTCCGCCCCGA  TTATCTCGGCTCTTTGAGGGCGAGGGTCTGCGTACTCCGTTTCTGTCTCTGTTTGTATTCCCCT 
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